Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10780755 | 0.76 | TSHR (0.37) | PGRAR | |
| SCHEMBL28232147 | 0.72 | CYP2A6 (0.33) | — | |
| SCHEMBL7299622 | 0.71 | PGR (0.30) | PGRAR | |
| SCHEMBL653188 | 0.71 | — | — | |
| SCHEMBL328971 | 0.70 | TSHR (0.39) | — | |
| SCHEMBL744484 | 0.70 | — | — | |
| SCHEMBL28063320 | 0.69 | CYP11B1 (0.30) | — | |
| SCHEMBL28186023 | 0.69 | VCAM1 (0.38) | — | |
| SCHEMBL152358 | 0.68 | TSHR (0.39) | PGRAR | |
| SCHEMBL31399295 | 0.68 | TSHR (0.39) | PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111825660-A | Compound, thermal activation delayed fluorescence material, organic electroluminescent device and application | 北京鼎材科技有限公司 | 2020-10-27 | — | — | CN | claimed |
| CN-101472924-A | KV1.5 potassium channel inhibitors | WYETH CORP (US) | 2009-07-01 | — | — | CN | claimed |
| EP-2035420-A2 | KV1.5 POTASSIUM CHANNEL INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-03-18 | — | — | EP | claimed |
| US-7402589-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-07-22 | — | — | US | claimed |
| WO-2007149873-A2 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | WO | claimed |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| EP-1737830-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1419128-A4 | IMPROVED HYDROLYTIC KINETIC RESOLUTION OF EPOXIDES | RHODIA PHARMA SOLUTION INC FOR (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2005105757-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | claimed |
| EP-1419128-A1 | IMPROVED HYDROLYTIC KINETIC RESOLUTION OF EPOXIDES | Rhodia Pharma Solution Inc., (formally Rhodia Chirex Inc.) (US) | 2004-05-19 | — | — | EP | claimed |
| US-6693206-B2 | USING COBALT COMPLEX CATALYST | RHODIA CHIREX, INC. | 2004-02-17 | — | — | US | claimed |
| US-20030073855-A1 | Hydrolytic kinetic resolution of epoxides | RHODIA CHIREX, INC. | 2003-04-17 | — | — | US | claimed |
| WO-2003018520-A1 | IMPROVED HYDROLYTIC KINETIC RESOLUTION OF EPOXIDES | RHODIA PHARMA SOLUTIONS INC. (US) | 2003-03-06 | — | — | WO | claimed |
| WO-2024135508-A1 | COMPOUND, ORGANIC THIN FILM, PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, PHOTOSENSOR AND SOLID-STATE IMAGING DEVICE | 三菱瓦斯化学株式会社 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024038818-A1 | FUSED-RING POLYAZAACENE COMPOUND, AND PHOTOELECTRIC CONVERSION ELEMENT OR ORGANIC ELECTRONIC ELEMENT CONTAINING SAME | 東ソー株式会社 | 2024-02-22 | — | — | WO | disclosed |
| WO-2023167234-A1 | COMPOUND, ORGANIC THIN FILM, PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, PHOTOSENSOR AND SOLID-STATE IMAGING DEVICE | 三菱瓦斯化学株式会社 | 2023-09-07 | — | — | WO | disclosed |
| EP-0275501-B1 | PROCESS FOR THE PREPARATION OF (Z)-2-(2-ARYLETHENYL)-ARYLCARBOXYLIC ACIDS | BASF Aktiengesellschaft (DE) | 1991-03-06 | — | — | EP | disclosed |
| US-4857658-A | Preparation of (Z)-2-(2-arylethenyl)arylcarboxylic acids | BASF AKTIENGESELLSCHAFT (DE) | 1989-08-15 | — | — | US | disclosed |
| EP-0275501-A1 | Process for the preparation of (Z)-2-(2-arylethenyl)-arylcarboxylic acids | BASF Aktiengesellschaft (DE) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | PGR 4118/4885AR 4719/4885 |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNA5, KCNH1, KCNK5 | PGR 4781/4885AR 2503/4885 |
| US-20030073855-A1 | Hydrolytic kinetic resolution of epoxides | EPHX2, EPHX1, POR | PGR 2755/4885AR 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.